VISEN PHARMA-B (02561) Rises Over 4% as Palopegteriparatide Completes First Prescription in Boao

Stock News

Nov 03

VISEN PHARMA-B (02561) surged over 4%, reaching HK$39.8 by the time of writing, marking a 4.68% increase. The uptick follows the recent first prescription of Palopegteriparatide (TransCon PTH) at Ruijin Hospital Hainan Hospital (Boao Research Hospital) under Shanghai Jiao Tong University School of Medicine.

The drug, already approved in major European and American markets, is the world's first and only hormone replacement therapy for hypoparathyroidism. CEO and Executive Director Lu Anbang emphasized that this milestone underscores VISEN PHARMA's commitment to innovation in endocrinology. The breakthrough therapy aims to alleviate challenges faced by patients under conventional treatments.

The company plans to accelerate domestic approval through collaborations while expanding its pipeline. Its most advanced candidate, Lonapegsomatropin (long-acting growth hormone), is expected to launch domestically in H2 2025 as China's third long-acting growth hormone therapy.

VISEN PHARMA's portfolio includes two unique candidates: Navipeptide and Palopegteriparatide, with the latter targeting a 2025 year-end NDA submission. Earlier partnerships with WuXi Biologics (June 2024) for localized production and Anke Biotechnology (July 2024) for commercialization highlight its strategy to deliver cost-effective therapies to patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1101244851"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1101244851\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1101244851?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 10:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101244851","market":"sh","top_or_hot":-1,"title":"VISEN PHARMA-B (02561) Rises Over 4% as Palopegteriparatide Completes First Prescription in Boao","media":"Stock News","content":"<p>VISEN PHARMA-B (02561) surged over 4%, reaching HK$39.8 by the time of writing, marking a 4.68% increase. The uptick follows the recent first prescription of Palopegteriparatide (TransCon PTH) at Ruijin Hospital Hainan Hospital (Boao Research Hospital) under Shanghai Jiao Tong University School of Medicine.</p>\n<p>The drug, already approved in major European and American markets, is the world's first and only hormone replacement therapy for hypoparathyroidism. CEO and Executive Director Lu Anbang emphasized that this milestone underscores VISEN PHARMA's commitment to innovation in endocrinology. The breakthrough therapy aims to alleviate challenges faced by patients under conventional treatments.</p>\n<p>The company plans to accelerate domestic approval through collaborations while expanding its pipeline. Its most advanced candidate, Lonapegsomatropin (long-acting growth hormone), is expected to launch domestically in H2 2025 as China's third long-acting growth hormone therapy.</p>\n<p>VISEN PHARMA's portfolio includes two unique candidates: Navipeptide and Palopegteriparatide, with the latter targeting a 2025 year-end NDA submission. Earlier partnerships with WuXi Biologics (June 2024) for localized production and Anke Biotechnology (July 2024) for commercialization highlight its strategy to deliver cost-effective therapies to patients.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN PHARMA-B (02561) Rises Over 4% as Palopegteriparatide Completes First Prescription in Boao</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN PHARMA-B (02561) Rises Over 4% as Palopegteriparatide Completes First Prescription in Boao\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-03 10:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN PHARMA-B (02561) surged over 4%, reaching HK$39.8 by the time of writing, marking a 4.68% increase. The uptick follows the recent first prescription of Palopegteriparatide (TransCon PTH) at Ruijin Hospital Hainan Hospital (Boao Research Hospital) under Shanghai Jiao Tong University School of Medicine.</p>\n<p>The drug, already approved in major European and American markets, is the world's first and only hormone replacement therapy for hypoparathyroidism. CEO and Executive Director Lu Anbang emphasized that this milestone underscores VISEN PHARMA's commitment to innovation in endocrinology. The breakthrough therapy aims to alleviate challenges faced by patients under conventional treatments.</p>\n<p>The company plans to accelerate domestic approval through collaborations while expanding its pipeline. Its most advanced candidate, Lonapegsomatropin (long-acting growth hormone), is expected to launch domestically in H2 2025 as China's third long-acting growth hormone therapy.</p>\n<p>VISEN PHARMA's portfolio includes two unique candidates: Navipeptide and Palopegteriparatide, with the latter targeting a 2025 year-end NDA submission. Earlier partnerships with WuXi Biologics (June 2024) for localized production and Anke Biotechnology (July 2024) for commercialization highlight its strategy to deliver cost-effective therapies to patients.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1101244851","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101244851","pubTimestamp":1762136899,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VISEN PHARMA-B (02561) surged over 4%, reaching HK$39.8 by the time of writing, marking a 4.68% increase. The uptick follows the recent first prescription of Palopegteriparatide (TransCon PTH) at...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02561":"维升药业-B"},"translate_title":"帕洛培特立帕肽在博鳌完成首个处方，维森制药-B(02561)涨超4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN PHARMA-B (02561) surged over 4%, reaching HK$39.8 by the time of writing, marking a 4.68% increase. The uptick follows the recent first prescription of Palopegteriparatide (TransCon PTH) at Ruijin Hospital Hainan Hospital (Boao Research Hospital) under Shanghai Jiao Tong University School of Medicine.\nThe drug, already approved in major European and American markets, is the world's first and only hormone replacement therapy for hypoparathyroidism. CEO and Executive Director Lu Anbang emphasized that this milestone underscores VISEN PHARMA's commitment to innovation in endocrinology. The breakthrough therapy aims to alleviate challenges faced by patients under conventional treatments.\nThe company plans to accelerate domestic approval through collaborations while expanding its pipeline. Its most advanced candidate, Lonapegsomatropin (long-acting growth hormone), is expected to launch domestically in H2 2025 as China's third long-acting growth hormone therapy.\nVISEN PHARMA's portfolio includes two unique candidates: Navipeptide and Palopegteriparatide, with the latter targeting a 2025 year-end NDA submission. Earlier partnerships with WuXi Biologics (June 2024) for localized production and Anke Biotechnology (July 2024) for commercialization highlight its strategy to deliver cost-effective therapies to patients.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}